InvestorsHub Logo
Followers 0
Posts 464
Boards Moderated 0
Alias Born 09/23/2014

Re: Ajax133 post# 71645

Monday, 02/08/2016 8:17:37 PM

Monday, February 08, 2016 8:17:37 PM

Post# of 424150
Amarin are simply running a large outcomes trial (SPA accepted by the FDA) to try and mirror as best they can the patient subset in JELIS that showed a 53% RRR in CVE's. R-IT has been designed and tweaked to give the best possible chance for the JELIS subset trial results to be replicated in a western population. Is that simple enough for you?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News